Phase 3
Completed N=121
An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)
Source: ClinicalTrials.gov NCT00796120 ↗Enrolled (actual)
121
Serious AEs
33.9%
Results posted
Sep 2014
Primary outcomePrimary: Progression - Free Survival (PFS) — 19.6; 8.3 months
Summary
The purpose of this study is to evaluate the efficacy and safety of trabectedin compared to standard doxorubicin in participants with advanced translocation-related sarcomas (cancer of connective tissue cells) (TRS).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Progression - Free Survival (PFS) |
19.6; 8.3 | — |
| SECONDARY 6-month Progression - Free Survival |
66.7; 78.3 | — |
| SECONDARY Percentage of Participants With Objective Response |
5.9; 27.0 | — |
| SECONDARY Overall Survival |
46.6; 33.5 | — |
| SECONDARY Duration of Response (DOR) |
NA; NA | — |
Eligibility Criteria
Inclusion Criteria
- Pathological diagnosis of translocation-related sarcomas (TRS) including the following subtypes: alveolar soft part sarcoma, angiomatoid fibrous histiocytoma, clear cell sarcoma, desmoplastic small round cell tumor, low grade endometrial stromal sarcoma (prior hormone therapy allowed), low grade fibromyxoid sarcoma, myxoid chondrosarcoma, myxoid/round cell liposarcoma (MRCL) and synovial sarcoma
- Participants must have unresectable locally advanced or metastatic progressive disease prior to enrolment
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0-2
- Adequate cardiac function, defined as left ventricular ejection fraction (LVEF) within normal limits according to institutional standards, as shown by echocardiography or scintigraphy multiple-gated acquisition scan [MUGA]
- Measurable disease as defined by the radiological (computed tomography [CT] scan and magnetic resonance imaging [MRI]) Response Evaluation Criteria in Solid Tumors (RECIST v.1.0) guidelines
Exclusion Criteria
- Known hypersensitivity to any components of the intravenous formulation of trabectedin or the comparators
- Prior chemotherapy treatment or irradiation of the lesion if only one target lesion is available
- Brain metastases and/or leptomeningeal metastases, even if treated
- Pregnant or lactating women or men and women of reproductive potential who are not using effective contraceptive methods
- History of another neoplastic disease (except basal cell carcinoma or cervical carcinoma in situ adequately treated) unless in remission for five years or more
Data sourced from ClinicalTrials.gov (NCT00796120). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.